目的 探讨喹硫平联合丙戊酸钠缓释片治疗阿尔茨海默病 (Alzheimer's disease, AD) 精神行为症状的临床疗效.方法 选取2015年2月-2018年1月本中心收治的AD精神行为症状患者108例为研究对象, 随机分为研究组与对照组, 各54例.对照组患者给予丙戊酸钠缓释片治疗, 研究组患者给予喹硫平联合丙戊酸钠缓释片治疗, 治疗结束后评价2组患者的临床疗效, 对比治疗前后阿尔茨海默病病理行为评分 (BEHAVE-AD) 、简明精神病评定量表 (BPRS) 评分、简易精神状态检查表 (MMSE) 评分、炎症因子及血管内皮指标水平, 并观察2组患者不良反应发生情况.结果 研究组患者的总有效率显著高于对照组 (P0.05) .结论 喹硫平联合丙戊酸钠缓释片治疗AD患者的精神行为症状疗效显著, 可有效控制患者精神行为症状, 并能使患者智力提高, 值得临床推广应用.%Objective To investigate the clinical efficacy of quetiapine combined with sodium valproate sustained release tablets in the treatment of the symptoms of Alzheimer′s disease (AD).Methods From February 2015to January 2018, 108AD patients with psychobehavioral symptoms were randomly divided into study group and control group with 54cases for each.Patients in the control group were treated with sodium valproate sustained-release tablets only, while patients in the study group with quetiapine combined with sodium valproate sustained-release tablets.The pathological behavior score (BEHAVE-AD) , intelligence score, (BPRS) score, inflammatory factor and vascular endothelial index were compared before and after treatment, and the adverse reactions of the two groups were observed.Results The total effective rate of the patients in the study group was significantly higher than that in the control group (P0.05).Conclusion Quetiapine combined with sodium valproate sustained-release tablets is effective in the treatment of mental and behavioral symptoms in AD patients.It can effectively control the mental and behavioral symptoms of AD patients and can improve the intelligence of patients.It is worth popularizing in clinical practice.
展开▼
